Health
AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets
AstraZeneca’s leadership hinted at where the cost cuts and job losses from the company’s new restructuring program might fall on a call with journalists Friday. “We are losing patent protection for Farxiga ...
- Published
- (1 h ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 33-word snippet. The full article is at the source.
More from Endpoints News and around the same time
Sanofi may seek higher European drug prices, not withhold launches, under Trump dealWhile some of Europe’s biggest drugmakers have warned that President Donald Trump’s pricing policies could leave European patients waiting longer for new medicines, Sanofi is taking a different approach. ...Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed backPlus news about Acumen, Bristol Myers Squibb, Regeneron, Aer Therapeutics and Hemay Pharmaceutical. Gilead pauses CAR-T after ICANS: After several cases of the neurological condition known as ICANS, Gilead said in ...Anthropic's Nathan Frey on biopharma partners, M&A and pipelineNathan Frey has stayed busy since Anthropic acquired his biotech startup Coefficient Bio this spring. The former Genentech machine-learning scientist now leads drug discovery and development research at the tech giant. Endpoints…Sanofi has no plans for a 'major' overhaul as Dupixent's patent cliff loomsIt’s been six months since Belén Garijo took over as the CEO for Sanofi, and the French drugmaker said Friday it is not planning “major” changes to its business or R&;D pipeline as the early ...After Be Bio shutdown, its CEO heads to Orbis; Enanta's longtime chief Jay Luly to retire→ Former Be Biopharma chief Joanne Smith-Farrell has landed at Orbis Medicines, an Eli Lilly- and Novo-backed startup that's developing oral macrocycles. Smith-Farrell replaces co-founder Morten Graugaard as CEO of Orbis ...Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio dealAfter shipping its precision epilepsy drug to Jazz Pharmaceuticals, Actio Biosciences has spun out the remainder of its genetics-driven pipeline into a new company called Setara Biosciences. Setara is getting a fresh $90 million…This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
